| Outline of Final Research Achievements |
Osteosarcoma is the most common primary malignancy in bone. Patients who respond poorly to chemotherapy are at higher risk of adverse prognosis. The molecular basis for such poor prognosis remains unclear. Thus, we tried to identify novel therapeutic targets for refractory osteosarcomas using gene expression analysis. Although osteosarcoma is generally known as a tumor with strong heterogeneity, tyrosine kinases PDGFRA, KDR and c-kit were aberrantly expressed in some cases. These tyrosine kinases may be candidates for novel therapeutic targets. In addition, aberrantly expression of several cell cycle-related genes, including TP53, CDKN2A, and CDKN2B, were associated with poor prognosis in osteosarcoma patients. Our findings indicate the possible application of predictive biomarkers and novel therapeutic targets.
|
